CHMP positive for Nemluvio (nemolizumab) for the treatment of both atopic dermatitis and prurigo nodularis – Galderma
Galderma announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting the marketing… read more.